Telomir Pharmaceuticals Files 2024 10-K

TL;DR

Telomir Pharma filed its 2024 10-K. Full financials out.

AI Summary

Telomir Pharmaceuticals, Inc. filed its 2024 10-K on February 4, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Miami, Florida, operates in the pharmaceutical preparations sector. Key financial data and operational details for the fiscal year 2024 are presented in this filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Telomir Pharmaceuticals' financial health and operational performance for the fiscal year 2024, including key financial statements and disclosures.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Telomir Pharmaceuticals is subject to significant regulatory, research and development, and market risks inherent in the industry.

Key Numbers

• 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
• 2025-02-04 — Filing Date (Date the 10-K was submitted to the SEC)

Key Players & Entities

• Telomir Pharmaceuticals, Inc. (company) — Filer of the 10-K
• 2024-12-31 (date) — Fiscal year end
• 2025-02-04 (date) — Filing date
• Miami, Florida (location) — Company headquarters
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $4.81 — company's common stock on such date of $4.81 per share, as reported by the NASDAQ Ca
• $966 billion — with annual healthcare costs exceeding $966 billion as of 2021. Existing treatments primari

Filing Documents

• form10-k.htm (10-K) — 1542KB
• ex31-1.htm (EX-31.1) — 14KB
• ex31-2.htm (EX-31.2) — 14KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• form10-k_001.jpg (GRAPHIC) — 107KB
• form10-k_002.jpg (GRAPHIC) — 31KB
• form10-k_03.jpg (GRAPHIC) — 20KB
• form10-k_004.jpg (GRAPHIC) — 77KB
• form10-k_005.jpg (GRAPHIC) — 121KB
• form10-k_007.jpg (GRAPHIC) — 13KB
• form10-k_008.jpg (GRAPHIC) — 10KB
• aud_001.jpg (GRAPHIC) — 57KB
• 0001493152-25-004872.txt ( ) — 6394KB
• telo-20241231.xsd (EX-101.SCH) — 27KB
• telo-20241231_cal.xml (EX-101.CAL) — 43KB
• telo-20241231_def.xml (EX-101.DEF) — 134KB
• telo-20241231_lab.xml (EX-101.LAB) — 324KB
• telo-20241231_pre.xml (EX-101.PRE) — 267KB
• form10-k_htm.xml (XML) — 543KB

Risk Factors

Risk Factors 19 Item 1B. Unresolved Staff Comments 46 Item 1C. Cybersecurity 46 Item 2. Description of Property 46 Item 3.

Legal Proceedings

Legal Proceedings 46 Item 4. Mine Safety Disclosure 46 PART II 47 Item 5. Market for Common Equity and Related Stockholder Matters 47 Item 6. [Reserved] 47 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 48 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 54 Item 8.

Financial Statements

Financial Statements 54 Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 54 Item 9A.

Controls and Procedures

Controls and Procedures 55 Item 9B. Other Information 55 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 55 PART III 55 Item 10. Directors, Executive Officers and Corporate Governance 55 Item 11.

Executive Compensation

Executive Compensation 61 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 70 Item 13. Certain Relationships and Related Transactions, and Director Independence 70 Item 14. Principal Accountant Fees and Services 72 PART IV 73 Item 15. Exhibits, Financial Statement Schedules 73

Signatures

Signatures 75 Unless we have indicated otherwise, or the context otherwise requires, references in this Report to "TELO," the "Company," "we," "us" and "our" or similar terms refer to Telomir Pharmaceuticals, Inc., a Florida corporation. From time to time, we may use our website, our Facebook page at https://www.facebook.com/people/Telomir-Pharmaceuticals-Inc/100087267737318/#, our Twitter at https://x.com/TelomirPharma, and on our LinkedIn account at https://www.linkedin.com/company/telomir-pharmaceuticals-inc/posts/?feedView=all to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.telomirpharma.com . Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website, our Facebook page, our Twitter posts and our LinkedIn posts are not incorporated into, and does not form a part of, this Annual Report. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act) that reflect our current expectations and views of future events . In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential", or "continue" or the negative of these terms or other similar expressions. In particular, statements about the markets in which we operate, including expectations regarding our studies, growth of our various markets, and our expectations, beliefs, plans, strategies, objectives, prospects, assumpti

View Full Filing

View this 10-K filing on SEC EDGAR